Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy

Medulloblastoma (MB) is the most common solid tumour in children and, despite current treatment with a rather aggressive combination therapy, accounts for 10% of all deaths associated with paediatric cancer. Breaking the tumour cells’ intrinsic resistance to therapy-induced cell death should lead to...

Full description

Bibliographic Details
Main Authors: Mike-Andrew Westhoff, Marie Schuler-Ortoli, Daniela Zerrinius, Amina Hadzalic, Andrea Schuster, Hannah Strobel, Angelika Scheuerle, Tiana Wong, Christian Rainer Wirtz, Klaus-Michael Debatin, Aurelia Peraud
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Pharmaceuticals
Subjects:
medulloblastoma
apoptosis
Bcl-2
Bcl-XL
ABT-199 (Venetoclax)
ABT-263 (Navitoclax)
Online Access:https://www.mdpi.com/1424-8247/15/1/91

Similar Items

Similar Items